卡培他滨和伊利替康联合热疗治疗晚期结直肠癌疗效观察

【目的】评价卡培他滨和伊利替康联合局部热疗方案治疗晚期结直肠癌的疗效与安全性。【方法】50例经病理组织学证实的晚期结直肠癌患者随机分为联合组和化疗组，每组均予伊利替康180mg／m^2静脉滴注，90min，d1；卡培他滨每日口服2500mg／m^2，连服两周治疗，联合治疗组在化疗d1、d4、d7、d10分别接受局部热疗，每次60min，每3周重复，完成2个周期后判定疗效。【结果】热疗组和化疗组的有效率（RR）分别为48％，40％（P〈0．05）。中住疾病进展时间分别为34周，28周（P〈0．05），中性粒细胞减少，恶心呕吐和腹泻是两组较为常见的毒副反应，热疗组较化疗组发生率明显减少（P〈0．05）。【结论】卡培他滨联合伊利替康加局部热疗治疗晚期结直肠癌的疗效高；局部热疗可降低化疗的毒副反应。

Effect of Capecitabine and Irinotecan Combined with Thermotherapy in Treating Advanced Colorectal Cancer

Objective]To evaluate the clinical efficacy and safety of thermotherapy combined with eapecitabine and irinoteean in patients with advanced colorectal cancer. Methods] Fifty histologically or cytologically confirmed advanced colorectal cancer patients were divided into two groups. Combined group received thermotherapy plus eapecitabine and irinotecan （capecitahine 2500mg/m^2 dividing two dose per oral on day 1 to 14, irinotecan 180mg/m^2 intravenously by dripping on day 1）. Chemotherapy group only received capecitabine and irinotecan（capecitabine 2500mg/m^2 dividing two dose per oral on day 1 to 14, irinotecan 180mg/m^2 intravenously by dripping on day 1）. They were treated every 3 weeks for at least 2 cycles. The response rate, time to progression （TTP） and safety were observed. Results] The response rate was 48% in combined thermother apy group and 40% in chemotherapy group（ P 〈0.05）. The median TTP was 34 weeks and 28 weeks for combined thermotherapy group and chemotherapy group, respectively（ P 〈0.05）. The main toxicities of the two groups were hematological toxicities, nausea and vomiting, and diarrhea. There was significant difference in the incidence of toxicity between two groups （ P 〈0.05）. Conclusion]Thermotherapy combined with capecitabine and irinotecan for advanced colorectal cancer shows a better chemotherapeutic effect and less toxicity than those of capecitabine and irinotecan alone.